4-[(2,2-Dimethylpropionyl)amino]buttersure

BeschreibungTonerg was launched in Italy for treatment of acute and post traumatic stress syndrome and "burnout" syndrome. It inhibits hypothalamic release of corticotropinreleasing factor (CRF) and effectively antagonizes the activation of CRF induced stress (neuroendocrine, autonomic and behavior responses). Tonerg is an atypical antidepressant because it does not involve the monoaminergic system and differs in effect from benzodiazepines (complete opposite effect of Diazepam). The entire molecule is responsible for activity. It is lipophilic, orally bioavailable, and has a halflife of 4-6 hr. Tonerg has a positive effect on sleep disorders by reducing insomnia, improving anxiety by 20% and depression by 23%.